The pharmaceutical industry plays a key role in enhancing both the health and wealth of the UK.
Over the years, patients in the National Health Service have been major beneficiaries of the many therapeutic advances made by the pharmaceutical companies operating in this country. The Health Departments in the UK and the ABPI have a common interest in ensuring that safe and effective medicines are available on reasonable terms to the NHS and in maintaining a strong, efficient and profitable pharmaceutical industry.
To ensure the future availability of new and improved medicines in this and other countries, the industry must be capable of sustained research and development. The Pharmaceutical Price Regulation Scheme is a voluntary agreement between the Government and the pharmaceutical industry aiming to create an environment where both these objectives can be achieved. The scheme was first introduced in 1957 and is generally renewed every five years or so. The current scheme runs for five years from January 2014.
The Pharmaceutical Price Regulation Scheme has played a significant role in the relationship between the industry, the NHS and the wider economy since its introduction in the early years of the NHS, but its mechanisms are complex and have not always been set out clearly and perhaps not widely understood.
The precise workings of the scheme are complex, and the full text of the 2014 PPRS is available on the
Department of Health website.
The 2014 Pharmaceutical Price Regulation Scheme became effective on 1 January 2014. The Department of Health (DH) is currently making arrangements to list those companies which have agreed to join the voluntary Scheme on the government website, but ABPI has agreed to post the list here as a temporary measure whilst that is being done. Please note that the list below is one prepared by the DH and ABPI is not responsible for its accuracy. If you believe your company is incorrectly cited, please contact the Department of Health directly. The list of companies having agreed to become members is up to date as of 27 January 2014. The DH has advised that 126 companies have joined the PPRS as of 1 January 2014 and a further 5 companies have expressed their willingness to join the scheme on 1 April 2014. Members will be aware that any company which is not subject to the voluntary scheme is automatically subject to the statutory scheme
A. Menarini Farmaceutica Internazionale SrlAbbott Group LtdAbbVie LimitedActavis UK LtdActelion Pharmaceuticals UK LimitedAegerion Pharmaceuticals LimitedAlcon Eye Care UK LtdAlexion Pharma UKAlimera Sciences, IncAlk-Abello LtdAllergan LimitedAlliance Pharmaceuticals LtdAlmirall UKAMCo LtdAmgen LimitedAOP Orphan LimitedArchimedes Pharma UK LtdARIAD Pharma (UK)Aspen HealthcareAspire Pharma LtdAstellasAstraZenecaBasilea Pharmaceuticals LimitedBausch & Lomb UK LimitedBaxterBayerBeacon PharmaceuticalsBesins Healthcare (UK) LimitedBiogen Idec International GmbhBiogen Idec LimitedBioMarin UK LtdBlue Bio PharmaceuticalsBoehringer IngelheimBristol Laboratories LtdBristol-Myers Squibb Pharmaceuticals LimitedBritannia Pharmaceuticals LtdCasen Fleet S.L.UCelgene LtdChanelle Medical U.K. LimitedChemidex Pharma LimitedChiesi LtdChugai Pharma UK LtdCliniMed LtdColgate-Palmolive (UK) LtdCreo Pharma LtdCTI Life SciencesD B Ashbourne LtdDaiichi-Sankyo UK LTDDerma UK LtdDermal LaboratoriesDesitin Pharma LtdDexcel Pharma LtdDHP Healthcare LtdDiscovery PharmaceuticalsDr Faulk Pharma UK LtdEisai LimitedEli Lilly & Company LimitedEssential Pharmaceuticals LimitedEumedica PharmaceuticalsFerndale Pharmaceuticals LtdFerring Pharmaceuticals LtdFlynn Pharma LimitedFocus Pharmaceutical LtdForest Laboratories UKFresenius Medical Care (UK) LtdGalderma (UK) LtdGambro UKGE HealthcareGedeon Richter (UK) LtdGenus PharmaceuticalsGlaxoSmithKline UK LtdGrunenthal LtdHenry Schein UK Holdings LimitedHK Pharma LtdInterMune UK & I LtdInternis Pharmaceuticals LtdIntrapharm Laboratories LimitedIpsen LtdJanssen-CilagKent Pharmaceuticals LtdKestrel Ophthalmics LtdKing Pharmaceuticals LtdLeoLucane PharmaLundbeckMarlborough PharmaceuticalsMartindale PharmaceuticalsMeda Pharmaceuticals LimitedMedac GmbHMerck Serono UKMerck Sharp & DohmeMerus Labs Luxco S.a R.L.Merz Pharma UK LtdMitsubishi Pharma EuropeMylanNapp Pharmaceutical HoldingsNeovii Biotech GmbHNordic PharmaNorgine Pharmaceuticals LimitedNovartis Pharmaceuticals LtdNovartis Vaccines & DiagnosticsNovo NordiskNPS Pharma International LtdOrion Pharma UK LtdOtsuka Pharmaceuticals (UK) LtdOxbridge Pharma LtdPfizerPharma Mar, S.A.Pharmacosmos UK LtdPharmasure LtdPharmaxis Pharmaceuticals LimitedPierre Fabre LimitedProfile Pharma LtdProStrakan Group plcPTC Therapeutics LtdRAD Neurim Pharmaceuticals EEC LimitedRapidscan Pharma SolutionsRecipharmReckitt BenckiserRocheRPH Pharmaceuticals ABSanofiSanofi Pasteur MSDSeptodont LtdServier Laboratories LtdShire Pharmaceuticals LtdSmith & Nephew HealthcareStirling Anglian Pharmaceuticals LtdStragen UK LimitedSucampo Pharma Europe LtdSun Pharmaceuticals UK LtdSunovion PharmaceuticalsSwedish Orphan Biovitrum Ltd (Sobi)Takeda UK LimitedTeva UK LtdThornton & Ross LimitedTillomed Laboratories LtdTillotts Pharma UK LimitedTMC Pharma LtdUCB Pharma LimitedVertex Pharmaceuticals UK LtdVifor Pharma UK LimitedWarner Chilcott UKWockhardt UK Ltd